



LIBRARIES
UNIVERSITY OF WISCONSIN - MADISON

Stromba advertisement.

[s.l.]: [s.n.], 1972

<https://digital.library.wisc.edu/1711.dl/N6PAE2FMLROA68R>

<http://rightsstatements.org/vocab/InC/1.0/>

The libraries provide public access to a wide range of material, including online exhibits, digitized collections, archival finding aids, our catalog, online articles, and a growing range of materials in many media.

When possible, we provide rights information in catalog records, finding aids, and other metadata that accompanies collections or items. However, it is always the user's obligation to evaluate copyright and rights issues in light of their own use.

Don't just
treat
the hole



Treat the whole!

Lipodermatosclerosis

Venous ulceration is simply the end point of a series of changes in the skin and subcutaneous tissues — the pain, induration, pigmentation and eczema collectively known as lipodermatosclerosis.¹ And for as long as the lipodermatosclerosis persists there is continual risk of ulceration and reulceration.

Basic problem—fibrin

The basic problem is pericapillary deposition of fibrin — exacerbated by a deficient fibrinolytic system — blocking diffusion of oxygen to the overlying epidermis, resulting in cellular death and venous ulceration.

Lifting the barrier

Fibrinolytic enhancement with Stromba lifts the fibrin barrier, resolves the lipodermatosclerosis and so reverses the ulceration process.² It is particularly effective when combined with elastic stocking support.³

Recurrence prevented

A five year follow-up study has shown that ulcer recurrence can be prevented by a single course of fibrinolytic enhancement supplemented by continuous use of elastic stockings.³



STROMBA

stanazolol

lifts the fibrin barrier— lets the whole leg heal.

¹ Br Med J 1982; 285(6348): 1071-1072. ² Br Med J 1980; 280: 7-11. ³ Progress in Fibrinolysis. 1983; 6: 526-528. **STROMBA** stanozolol For the complications of deep vein thrombosis as in lipodermatosclerosis, (pain, induration, pigmentation and eczema in the post-phlebitic syndrome). Each tablet contains stanozolol 5 mg. Bottles of 50 or 200 tablets. Basic NHS cost of one week's treatment (14 tablets ex 200 pack) £3.87. PL0071/5092. **Usual adult dose** 1 tablet twice daily. **Contra-indications** Cancer of the prostate, pregnancy, liver disease, porphyria. **Precautions** in patients with renal or cardiac disease or a history of liver disease. Prolonged use in children may lead to premature

closure of the epiphyses. The possibility of prolonged treatment with anabolic steroids inducing or enhancing the development of liver tumours cannot be excluded. Stromba may potentiate the action of warfarin type anti-coagulants. It may alter the ratio of high and low density lipoproteins. **Side-effects** Mild androgenic side-effects may occur and are reversible on stopping treatment. Headache, cramp, dyspepsia, euphoria and depression have been reported and occasionally cholestatic jaundice. Stromba is a registered trade mark. Further information available from:—
Sterling Research Laboratories, Onslow Street, Guildford, Surrey GU1 4YS.